Systémová enzymoterapie pro odborníky

Treatment of fibrocystic mastopathy with hydrolytic enzymes

F.-W. Dittmar^l, W. Luh²

^lDepartment of Obstetrics and Gynecology, Starnberg District Hospital, Academic Teaching Hospital of the Ludwig-Maximilians-University Munich, D-82319 Starnberg, FRG
²Department of Gynecology, Central Hospital "Links der Weser", D-28277 Bremen, FRG

International J. of Experimental and Clinical Chemotherapie 1993: Vol. 6, Nr. 1, pp. 9-20

WE 13 (5-03-1) = WE 49 (5-04-1) něm.

Abstract

Fibrocystic mastopathy affects about 50 % of all women in the course of their lives. Because of subjective symptoms, the risk of malignant degeneration (5 % of all cases), and ensuing physical and psychological stress, treatment of fibrocystic mastopathy is indispensable. So far, there is no causal therapy. Most common therapeutical regimens are associated with severe side effects.
Therefore, the effect of treatment with an enzyme combination preparation was compared with that of placebo in a randomized double blind study in 96 patients with mastopathy over a study period of 6 weeks.
At the start of the study both groups were well comparable with respect to all relevant study parameters. At the end of the study period there were significant differences regarding the parameters of effectiveness "diameter of the largest cyst" (p = 0.003), "subjective disturbance by symptoms" (p = 0.001) and "cumulative score of complaints" (p < 0.001). As far as the number of cysts is concerned, there was no significant difference at the end of the study period (p = 0.695). Bearing in mind, however, that the initial condition was somewhat worse in the group treated with enzymes, a tendency towards better effectiveness of the enzyme combination preparation was observed with respect to this criterion, too. The difference of absolute change was significant (p = 0.008). The assessment of effectiveness by physician and patient showed clear advantages of the enzyme therapy over placebo.
There was a higher number of mostly mild side effects in the enzyme group, but only stomach complaints and loose stool. Since tolerance was also comparable with that of placebo, the results obtained lead to the conclusion that the enzyme combination preparation lends itself to the symptomatic treatment of fibrocystic mastopathy. Further longer-term studies, including biopsies and determination of hormonal parameters, will clarify whether causal treatment of fibrocystic mastopathy is possible.

Key words: Fibrocystic mastopathy - enzyme therapy - enzyme combination preparation vs. placebo


Úvod pro odborníky O firmě Kontakty Pomáháme druhým Poradna
Zánět a jeho ovlivnění SET Zvýšení využitelnosti antibiotik proteolytickými enzymy Angiologie, flebologie Diabetologie Gynekologie Chirurgie, traumatologie, ortopedie Imunologie Lymfologie ORL Pediatrie Revmatologie Sportovní medicína Stomatologie Urologie Literatura Časopisy s Impact faktorem Ostatní literatura SPC Wobenzym SPC Phlogenzym	Treatment of fibrocystic mastopathy with hydrolytic enzymes F.-W. Dittmar^l, W. Luh² ^lDepartment of Obstetrics and Gynecology, Starnberg District Hospital, Academic Teaching Hospital of the Ludwig-Maximilians-University Munich, D-82319 Starnberg, FRG ²Department of Gynecology, Central Hospital "Links der Weser", D-28277 Bremen, FRG International J. of Experimental and Clinical Chemotherapie 1993: Vol. 6, Nr. 1, pp. 9-20 WE 13 (5-03-1) = WE 49 (5-04-1) něm. Abstract Fibrocystic mastopathy affects about 50 % of all women in the course of their lives. Because of subjective symptoms, the risk of malignant degeneration (5 % of all cases), and ensuing physical and psychological stress, treatment of fibrocystic mastopathy is indispensable. So far, there is no causal therapy. Most common therapeutical regimens are associated with severe side effects. Therefore, the effect of treatment with an enzyme combination preparation was compared with that of placebo in a randomized double blind study in 96 patients with mastopathy over a study period of 6 weeks. At the start of the study both groups were well comparable with respect to all relevant study parameters. At the end of the study period there were significant differences regarding the parameters of effectiveness "diameter of the largest cyst" (p = 0.003), "subjective disturbance by symptoms" (p = 0.001) and "cumulative score of complaints" (p < 0.001). As far as the number of cysts is concerned, there was no significant difference at the end of the study period (p = 0.695). Bearing in mind, however, that the initial condition was somewhat worse in the group treated with enzymes, a tendency towards better effectiveness of the enzyme combination preparation was observed with respect to this criterion, too. The difference of absolute change was significant (p = 0.008). The assessment of effectiveness by physician and patient showed clear advantages of the enzyme therapy over placebo. There was a higher number of mostly mild side effects in the enzyme group, but only stomach complaints and loose stool. Since tolerance was also comparable with that of placebo, the results obtained lead to the conclusion that the enzyme combination preparation lends itself to the symptomatic treatment of fibrocystic mastopathy. Further longer-term studies, including biopsies and determination of hormonal parameters, will clarify whether causal treatment of fibrocystic mastopathy is possible. *Key words*: Fibrocystic mastopathy - enzyme therapy - enzyme combination preparation vs. placebo
	Lék pro vnitřní užití. Čtěte pečlivě příbalovou informaci. Inzertní stránky společnosti MUCOS Pharma CZ, s.r.o. - tel: (+420)-267 750 003